DEVELOPMENT OF ANTICERAMIDE TREATMENT AS A NOVEL MEDICAL COUNTERMEASURE FOR ACUTE EFFECTS OF RADIATION EXPOSURE

开发抗酰胺治疗作为治疗辐射暴露急性影响的新型医学对策

• 批准号: 10932584
• 负责人: CHARLES DIMMLER III
• 金额: $ 152.95万
• 依托单位: CERAMEDIX HOLDING, LLC
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-01 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10932584
• 关键词: Acute; Address; Animal Experimentation; Apoptosis; Biological; Blood Vessels; Cessation of life; Development; Endothelium; FDA approved; Female; Injury; Ionizing radiation; Modeling; Mus; Organ failure; Pegfilgrastim; Radiation; Radiation Accidents; Radiation Injuries; Radiation Toxicity; Radiation exposure; Testing; Vascular Endothelium; biomarker development; gastrointestinal; irradiation; male; medical countermeasure; novel; radiation effect; radiation-induced injury; response

Ceramedix is developing CX-01, a promising radiation medical countermeasure (MCM), that addresses radiation-induced microvascular (endothelial) injury that leads to subsequent GI organ failure and death. CX-01 inhibits the initiating event of radiation injury and microvascular endothelial apoptosis. Currently, there are no FDA-approved treatments for gastrointestinal acute radiation syndrome (GI-ARS) The complexity of the biological responses to escalating radiation exposures has led to continued development of animal research platforms for reliably modeling different stages of ionizing radiation (IR) induced injury with tactical application to testing novel MCMs.

Ceramedix 正在开发 CX-01，这是一种很有前途的辐射医疗对策 (MCM)，可解决辐射引起的微血管（内皮）损伤，从而导致随后的胃肠道器官衰竭和死亡。 CX-01 抑制放射损伤和微血管内皮细胞凋亡的起始事件。目前，尚无 FDA 批准的治疗胃肠道急性辐射综合征 (GI-ARS) 的方法。对不断增加的辐射暴露的生物反应的复杂性导致了动物研究平台的持续开发，以可靠地模拟电离辐射 (IR) 诱导的不同阶段测试新型 MCM 的战术应用损伤。